Indoco Remedies · NSE: INDOCO · BSE: 532612
Q4 FY23 results · Jan–Mar 2023
Indoco Remedies reported revenue from operations of ₹428.16 crore (up 4.7% from Q4 FY22) and net profit of ₹25.81 crore (down 36.2% from Q4 FY22) for Q4 FY23 (Jan–Mar 2023), on a consolidated basis.
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 428.16 | 409.13 | +4.7% | 399.20 | +7.3% |
| Other income | 0.50 | 0.30 | +66.7% | 0.36 | +38.9% |
| Total income | 428.66 | 409.43 | +4.7% | 399.56 | +7.3% |
| Profit before tax | 38.93 | 59.75 | −34.8% | 38.22 | +1.9% |
| Net profit for the period | 25.81 | 40.45 | −36.2% | 28.14 | −8.3% |
| EPS, basic (₹) | 2.80 | 4.39 | −36.2% | 3.05 | −8.2% |
| Net margin (%) | 6.0 | 9.9 | 7.0 |
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 427.46 | 408.88 | +4.5% | 398.64 | +7.2% |
| Other income | 0.49 | 0.29 | +69.0% | 0.37 | +32.4% |
| Total income | 427.95 | 409.17 | +4.6% | 399.01 | +7.3% |
| Profit before tax | 38.33 | 59.68 | −35.8% | 37.85 | +1.3% |
| Net profit for the period | 25.37 | 40.37 | −37.2% | 27.87 | −9.0% |
| EPS, basic (₹) | 2.75 | 4.38 | −37.2% | 3.02 | −8.9% |
| Net margin (%) | 5.9 | 9.9 | 7.0 |
Consolidated
- Filed with BSE
- 24 May 2023, 12:53 IST
- Board meeting
- 23 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 24 May 2023, 12:53 IST
- Board meeting
- 23 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE